Vesugen is a 3-amino-acid peptide (Lys-Glu-Asp, or KED) from the Khavinson research group. It's marketed as a vascular tool for age-related blood vessel decline. We find the mechanism story internally consistent. The independent evidence base is thin in exactly the same way the rest of the Khavinson short-peptide program is thin.
Vesugen is a synthetic 3-amino-acid peptide with sequence Lys-Glu-Asp (KED), developed by Vladimir Khavinson and colleagues in Saint Petersburg. It belongs to the same family as Epitalon (AEDG), Pinealon (EDR), and Cartalax (AED). The intended use: age-related vascular decline.
Zero Western randomized trials of Vesugen in humans appear in PubMed for 2020-2026. The supporting literature is rat studies on brain microcirculation. A single Russian research group publishes ~10 of the ~12 papers on KED. Not FDA-approved. Not EMA-approved. Used in Russia under Russian rules. Our read: Vesugen is a cell-culture and rodent tool, not a translated therapeutic.
Vesugen sits in a curious spot. The research lineage is real. The Khavinson group has been publishing on these short peptides since the 1970s. Their broader program has produced internally consistent findings on microvessel density in aged rats and gene expression in cell culture.
But one consortium publishes nearly all the data. That single-source dominance matters to us. The evidence is real but narrow. It's not Western randomized-trial grade.
This peptide is one of the harder ones for us to write about honestly. Consumer marketing leans on "Russian science endorsed" framing without flagging the methodological gap. The molecular biology isn't made up. The Russian clinical reports aren't nothing. But neither is the same as a Cochrane-grade Phase III trial. The gap between preclinical observation and a validated therapeutic claim is substantial here.
What Vesugen is at the molecular level
The sequence is three amino acids: Lys-Glu-Asp (KED). Molecular weight around 390 g/mol. The Khavinson group synthesized it as one of a series of short "cytogens." Each cytogen is tied to a specific tissue. KED was designated the vascular one.
The pattern repeats across 6+ peptides in the family. Epitalon (AEDG) targets the pineal gland. Pinealon (EDR) targets neurons. Vesugen (KED) targets blood vessels.
The proposed mechanism is gene-expression modulation at very low (nanomolar) doses. The 2015 paper from Khavinson et al. in Advances in Gerontology framed it in epigenetic terms. Short peptides bind chromatin (the DNA-protein scaffolding inside the nucleus) and alter how endothelial cell genes get read.
The 2021 follow-up from the same group (Khavinson, Lin'kova & Umnov, 2021) extended the framing to Alzheimer's-related neurogenesis. We see this pattern repeatedly in the group's work. Mechanistic claims accumulate across many disease indications over many years.
The proposed mechanism is the same template the Khavinson group applies to Epitalon, Pinealon, Cartalax, and Vesugen. Each peptide is positioned to a different tissue. The mechanistic richness is partly an artifact of one consortium exploring related endpoints with related compounds over many years.
— Our synthesis across the Khavinson literature, 2009-2021
The rat microcirculation data: what was shown
The clearest preclinical signal for Vesugen comes from 2 related papers by Sokolova and colleagues (a Khavinson-group collaborator). The 2016 paper in Bulletin of Experimental Biology and Medicine (Sokolova et al., 2016) showed that intramuscular vascular peptide treatment increased the density of small blood vessels in the brain cortex of aged rats vs age-matched controls.
The 2018 follow-up in Advances in Gerontology (Sokolova et al., 2018) extended the finding to spontaneously hypertensive rats. They reported cumulative effects on cortical blood flow across repeated dosing cycles.
Both studies are real preclinical work. We won't dismiss them. But both come from within the Khavinson consortium, not independent Western validation. Sample sizes are modest. The endpoints (microvessel density under a microscope) are reasonable preclinical measures. Still, they remain several methodological steps removed from a Western Phase II endpoint like flow-mediated dilation or a clinical cardiovascular outcome. That's the standard Khavinson-cytogen translation gap we see across the program.
Vesugen (KED)
Vesugen is on the Peptriva research roadmap and not currently stocked. It's the reference compound cited across the Khavinson microvessel studies in this review. We're evaluating sourcing with the same identity-verification standards we apply to every cytogen we carry.
Where this falls short: the single-source-dominance problem
What the data doesn't show. Across the entire Khavinson cytogen family (Epitalon, Pinealon, Cartalax, Vesugen, Livagen, Vilon) the same evidence pattern repeats. One consortium publishes nearly all the preclinical and cell-culture work over many years. Mechanistic claims accumulate. Independent Western groups occasionally publish on individual compounds. But the Khavinson output dwarfs the independent validation, and heavy internal cross-citation makes the program look more validated than independent assessment would support.
For Vesugen specifically, our literature search comes up sparser than for Epitalon. Where Epitalon has at least 1 recent independent paper (Brunel, 2025), Vesugen's recent literature is essentially all Khavinson-affiliated.
The 2009 Biogerontology review from Anisimov & Khavinson remains the broadest Western-language framing we've found. Beyond that, the literature is in Bulletin of Experimental Biology and Medicine, Advances in Gerontology, and other journals where the Khavinson group's presence is concentrated.
What this means for research use
Our honest framing for a Western researcher considering Vesugen:
- Cell-culture and rodent work is reasonable. The preclinical signal on microvessel density and brain blood flow is real. For studies investigating short-peptide effects on endothelial cell growth, VEGF signaling, or aging-related vascular biology, KED can serve as a tool compound. The single-source-dominance caveat warrants disclosure in any publication drawing on this literature.
- Chronic human self-administration is different ground. The mechanism is proposed but not characterized. The safety data we have is acute-toxicity rodent work, not chronic human safety monitoring. The Western trials that would convert "Russian clinical practice peptide" into "evidence-grade therapeutic" haven't been done in 50 years.
- Consumer marketing outpaces the evidence. Copy framing Vesugen as a treatment for "vascular aging" or "endothelial dysfunction" in humans makes clinical claims the available literature does not support. Such framing reflects commercial positioning, not peer-reviewed validation.
Vesugen (KED)
Synthetic Lys-Glu-Asp tripeptide. The reference compound used across the cited Khavinson microvessel studies. We don't stock Vesugen yet. When we do, identity will be confirmed by mass spectrometry with a lot-specific CoA from an ISO 17025 third-party lab. Browse our cytogen-class catalog for Epitalon and adjacent reference compounds.
Frequently asked questions
What is Vesugen?
Vesugen is the brand name for a synthetic 3-amino-acid peptide (sequence Lys-Glu-Asp, KED) developed by the Khavinson group in Saint Petersburg. It's one of several short peptides ("cytogens") the group has positioned as blood-vessel agents for age-related decline. Most of the supporting research is Russian-language preclinical work from the same consortium.
What is a Khavinson cytogen?
The Khavinson program has produced a family of short synthetic peptides (mostly 3- and 4-amino-acid compounds) the group calls cytogens or peptide bioregulators. Each one is claimed to target a specific tissue. Epitalon (AEDG) targets pineal/longevity. Pinealon (EDR) targets neurons. Cartalax (AED) targets cartilage. Vesugen (KED) targets blood vessels. The pattern is consistent: a short peptide derived from an organ extract, proposed to bind chromatin and modulate gene expression at low concentrations, with most efficacy data generated by the same consortium.
Is Vesugen FDA-approved?
No. Vesugen is not FDA-approved and not EMA-approved. It's used in Russia under the Russian regulatory framework as part of the Khavinson cytogen product line. There are no PubMed-indexed Western randomized trials of Vesugen in humans for any vascular indication. US sale is limited to research-use-only laboratory reference compound.
What is the proposed mechanism?
The Khavinson group's proposed mechanism for KED is gene-expression modulation in blood-vessel endothelial cells. The peptide is said to bind chromatin or RNA and alter which endothelial genes are turned on. Animal studies from the group report increased microvessel density and better brain blood flow in aged and hypertensive rats. Independent Western validation is sparse. The mechanism mirrors what the same group proposes for Epitalon and Pinealon, and it shares their evidence-base limitations.
Where can I read more on the Khavinson school?
Our research library covers the Khavinson school in depth. The Epitalon complete guide walks through the AEDG telomerase claims and the 2025 Brunel paper on cancer-cell ALT activation. The Russian-school cognitive peptides overview frames the broader category (Selank, Semax, Epitalon, DSIP) against Western trial methodology. Both share the same provenance and evidence-quality frame that applies to Vesugen.
Is Vesugen safe for research use?
Acute toxicity data from rat studies is reassuring. Short peptides at Khavinson-group doses haven't caused acute adverse signals in animals. But chronic safety data in humans is essentially absent. The proposed gene-expression mechanism raises theoretical concerns about long-term effects on cell growth and autoimmunity. There's no Western safety-monitoring system tracking adverse events in Russia-supplied Vesugen users. Research-grade use in cell or rodent studies is different from chronic human self-administration.
What to know now
- Identity: synthetic tripeptide Lys-Glu-Asp (KED), MW ~390 g/mol. The Khavinson group's designated "vascular cytogen."
- Provenance: developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Most of the efficacy literature comes from the same single research consortium.
- Mechanism claim: short-peptide gene-expression modulation in blood-vessel cells, proposed to act via chromatin or RNA binding at low doses.
- Preclinical signal: two Sokolova-Khavinson papers report increased microvessel density and better brain blood flow in aged and hypertensive rats.
- Human trial evidence: zero Western randomized trials of Vesugen in humans for any indication in 2020-2026.
- Regulatory: not FDA-approved. Not EMA-approved. Used in Russia under Russian regulation. Not currently listed by WADA.
- Our honest framing: a research-grade tool for cell-culture and rodent work, with the same single-source-dominance caveat that applies to the rest of the Khavinson cytogen family. Not a translated therapeutic.
What we're watching
Two things over the next 24-36 months. First, whether any independent Western or Asian research group registers a randomized trial of Vesugen for a vascular indication. The molecular biology supports it, and the kind of small, well-controlled trial that would convert "Russian clinical practice peptide" into evidence-grade therapeutic hasn't been done in 50 years. Second, whether any independent group reproduces the Sokolova-Khavinson microvessel density findings in aged rodents. One independent replication would meaningfully shift our evidence-quality framing for KED specifically and the Khavinson program more broadly.
References
- Anisimov, V. N., & Khavinson, V. K. (2009). Peptide bioregulation of aging: Results and prospects. Biogerontology, 11(2), 139–149. https://doi.org/10.1007/s10522-009-9249-8
- Sokolova, I. B., Ryzhak, G. A., Mel’nikova, E. V., Sergeev, I. V., & Khavinson, V. K. (2016). Effects of vascular peptide bioregulator on the density of microvascular network in the brain cortex of aged rats. Bulletin of Experimental Biology and Medicine, 161(4), 569–572. https://doi.org/10.1007/s10517-016-3400-8
- Sokolova, I. B., Ryzhak, G. A., & Khavinson, V. K. (2018). Functional cumulation of the influence of vascular peptide bioregulator on microcirculation in the brain cortex of spontaneously hypertensive rats. Advances in Gerontology, 8(2), 119–123. https://doi.org/10.1134/s2079057018020170
- Khavinson, V. K., Tarnovskaya, S. I., Linkova, N. S., Gutop, E. O., & Elashkina, E. V. (2015). Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation in aging. Advances in Gerontology, 5(4), 217–220. https://doi.org/10.1134/s2079057015040116
- Khavinson, V. K., Lin’kova, N. S., & Umnov, R. S. (2021). Peptide KED: Molecular-genetic aspects of neurogenesis regulation in Alzheimer’s disease. Bulletin of Experimental Biology and Medicine, 171(2), 190–193. https://doi.org/10.1007/s10517-021-05192-6